Clinical trial
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
ClinicalTrials.gov ID: NCT05906628
Sponsor: Incyte Corporation
Information provided by: Incyte Corporation (Responsible Party)
Last Update Posted: 2024-04-10
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).
Official Title:
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
Intervention / Treatment:
Drug: Ruxolitinib cream
Drug: Vehicle
| Category | Value |
|---|---|
| Study Start (Actual) | 2023-07-31 |
| Primary Completion (Estimated) | 2024-08-26 |
| Study Completion (Estimated) | 2025-01-17 |
| Enrollment (Actual) | 186 |
| Study Type | Interventional |
| Phase | Phase 2 |
| Other Study ID Numbers |
INCB 18424-226
2022-502827-23-00 (Registry Identifier) (REGISTRY: EU CT Number) |